1-20 of 28
Francis J. Giles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies

Benedito A. Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L. Coveler, Steven Powell, Bruno Bastos, Elizabeth Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor Weiskittel, Hu Li, Brittany A. Borden, R. Donald Harvey, Solmaz Sahebjam, Andres Cervantes, Austin Koukol, Andrew P. Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J. Giles, Pamela Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1916
Published: 20 November 2023
View article titled, Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies
Open the PDF for Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies in another window
Includes: Supplementary data
Journal Articles

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernadó-Morales, Noemí Haro, Francis J. Giles, Óscar J. Pozo, Josep M. Miquel, Paolo G. Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquín Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V. Tian
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 432–445.
https://doi.org/10.1158/1078-0432.CCR-22-2551
Published: 17 January 2023
View article titled, Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Open the PDF for Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation in another window
Includes: Supplementary data
Journal Articles

Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR–mediated DNA Damage Response

Li Ding, Vijay S. Madamsetty, Spencer Kiers, Olga Alekhina, Andrey Ugolkov, John Dube, Yu Zhang, Jin-San Zhang, Enfeng Wang, Shamit K. Dutta, Daniel M. Schmitt, Francis J. Giles, Alan P. Kozikowski, Andrew P. Mazar, Debabrata Mukhopadhyay, Daniel D. Billadeau
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4128.
https://doi.org/10.1158/1078-0432.CCR-21-2114
Published: 15 July 2021
View article titled, Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR–mediated DNA Damage Response
Open the PDF for Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR–mediated DNA Damage Response in another window
Journal Articles

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip P. Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha H. Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain Hayward, Christine McLeod, Helen X. Chen, Elad Sharon, Edward Mayerson, Christopher W. Ryan, Melissa Plets, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2290–2296.
https://doi.org/10.1158/1078-0432.CCR-19-3356
Published: 15 May 2020
View article titled, A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Open the PDF for A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors in another window
Includes: Supplementary data
Journal Articles

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response

Li Ding, Vijay S. Madamsetty, Spencer Kiers, Olga Alekhina, Andrey Ugolkov, John Dube, Yu Zhang, Jin-San Zhang, Enfeng Wang, Shamit K. Dutta, Daniel M. Schmitt, Francis J. Giles, Alan P. Kozikowski, Andrew P. Mazar, Debabrata Mukhopadhyay, Daniel D. Billadeau
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6452–6462.
https://doi.org/10.1158/1078-0432.CCR-19-0799
Published: 01 November 2019
View article titled, Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response
Open the PDF for Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response in another window
Includes: Supplementary data
Journal Articles

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial

Naseema Gangat, Christian Marinaccio, Ronan Swords, Justin M. Watts, Sandeep Gurbuxani, Alfred Rademaker, Angela J. Fought, Olga Frankfurt, Jessica K. Altman, Qiang Jeremy Wen, Noushin Farnoud, Christopher A. Famulare, Akshar Patel, Roberto Tapia, Rangit R. Vallapureddy, Stephanie Barath, Amy Graf, Amy Handlogten, Darci Zblewski, Mrinal M. Patnaik, Aref Al-kali, Yvonne Trang Dinh, Kristen Englund Prahl, Shradha Patel, Juan Carlos Nobrega, Dalissa Tejera, Amber Thomassen, Juehua Gao, Peng Ji, Raajit K. Rampal, Francis J. Giles, Ayalew Tefferi, Brady Stein, John D. Crispino
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4898–4906.
https://doi.org/10.1158/1078-0432.CCR-19-1005
Published: 15 August 2019
View article titled, Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Open the PDF for Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

Benedito A. Carneiro, Sahithi Pamarthy, Ami N. Shah, Vinay Sagar, Kenji Unno, HuiYing Han, Ximing J. Yang, Rubens B. Costa, Rebecca J. Nagy, Richard B. Lanman, Timothy M. Kuzel, Jeffrey S. Ross, Laurie Gay, Julia A. Elvin, Siraj M. Ali, Massimo Cristofanilli, Young K. Chae, Francis J. Giles, Sarki A. Abdulkadir
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-18-0332
Published: 14 June 2018
View article titled, Anaplastic Lymphoma Kinase Mutation (<em>ALK</em> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
Open the PDF for Anaplastic Lymphoma Kinase Mutation (<em>ALK</em> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib in another window
Includes: Supplementary data
Journal Articles

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors

Denis L. Jardim, Débora de Melo Gagliato, Francis J. Giles, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1785–1794.
https://doi.org/10.1158/1078-0432.CCR-17-1970
Published: 12 April 2018
View article titled, Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
Open the PDF for Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Matthew Genet, Galina Gritsina, Balázs Győrffy, Priscilla K. Brastianos, David C. Binder, Jeffrey A. Sosman, Francis J. Giles, Charles D. James, Craig Horbinski, Roger Stupp, Derek A. Wainwright
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (21): 6650–6660.
https://doi.org/10.1158/1078-0432.CCR-17-0120
Published: 31 October 2017
View article titled, Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Open the PDF for Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer

Amy Walz, Andrey Ugolkov, Sunandana Chandra, Alan Kozikowski, Benedito A. Carneiro, Thomas V. O'Halloran, Francis J. Giles, Daniel D. Billadeau, Andrew P. Mazar
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 1891–1897.
https://doi.org/10.1158/1078-0432.CCR-15-2240
Published: 13 April 2017
View article titled, Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Open the PDF for Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer in another window
Journal Articles

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

Lijie Zhai, Stefani Spranger, David C. Binder, Galina Gritsina, Kristen L. Lauing, Francis J. Giles, Derek A. Wainwright
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5427–5433.
https://doi.org/10.1158/1078-0432.CCR-15-0420
Published: 14 December 2015
View article titled, Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Open the PDF for Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy in another window
Journal Articles

Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting

Jessica K. Altman, Amy Szilard, Dennis J. Goussetis, Antonella Sassano, Marco Colamonici, Elias Gounaris, Olga Frankfurt, Francis J. Giles, Elizabeth A. Eklund, Elspeth M. Beauchamp, Leonidas C. Platanias
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2400–2409.
https://doi.org/10.1158/1078-0432.CCR-13-3218
Published: 30 April 2014
View article titled, Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting
Open the PDF for Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting in another window
Journal Articles

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

Andrew J. Brenner, Yael C. Cohen, Eyal Breitbart, Livnat Bangio, John Sarantopoulos, Francis J. Giles, Ernest C. Borden, Dror Harats, Pierre L. Triozzi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (14): 3996–4007.
https://doi.org/10.1158/1078-0432.CCR-12-2079
Published: 15 July 2013
View article titled, Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Monica Mita, Kevin R. Kelly, Alain Mita, Alejandro D. Ricart, Ofelia Romero, Anthony Tolcher, Laurel Hook, Chukwuemeka Okereke, Ilya Krivelevich, Daniel P. Rossignol, Francis J. Giles, Eric K. Rowinsky, Chris Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (1): 193–200.
https://doi.org/10.1158/1078-0432.CCR-10-0010
Published: 04 January 2011
View article titled, Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
Open the PDF for Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies in another window
Journal Articles

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Devalingam Mahalingam, Ernest C. Medina, Juan A. Esquivel, II, Claudia M. Espitia, Sabrina Smith, Kelli Oberheu, Ronan Swords, Kevin R. Kelly, Monica M. Mita, Alain C. Mita, Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 141–153.
https://doi.org/10.1158/1078-0432.CCR-09-1385
Published: 04 January 2010
View article titled, Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Open the PDF for Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels in another window
Journal Articles

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Alain C. Mita, Monica M. Mita, Steffan T. Nawrocki, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5000–5005.
https://doi.org/10.1158/1078-0432.CCR-08-0746
Published: 12 August 2008
View article titled, Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Open the PDF for Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics in another window
Journal Articles

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

David A. Rizzieri, Eric Feldman, John F. DiPersio, Nashat Gabrail, Wendy Stock, Roger Strair, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2756–2762.
https://doi.org/10.1158/1078-0432.CCR-07-1372
Published: 01 May 2008
View article titled, A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Srdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, David Harris, Jorge Cortes, Francis J. Giles, Hagop Kantarjian, Waldemar Priebe, Zeev Estrov
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 788–796.
https://doi.org/10.1158/1078-0432.CCR-07-0524
Published: 01 February 2008
View article titled, WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation
Open the PDF for WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation in another window
Journal Articles

Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

Razelle Kurzrock, Hagop M. Kantarjian, Michelle A. Blascovich, Cindy Bucher, Srdan Verstovsek, John J. Wright, Susan R. Pilat, Jorge E. Cortes, Elihu H. Estey, Francis J. Giles, Miloslav Beran, Said M. Sebti
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 509–514.
https://doi.org/10.1158/1078-0432.CCR-07-1532
Published: 25 January 2008
View article titled, Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Open the PDF for Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window